Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.04 Million EUR | -31.91% |
| 2022 | 3 Million EUR | -42.74% |
| 2021 | 5.25 Million EUR | -9.21% |
| 2020 | 5.78 Million EUR | 32.07% |
| 2019 | 4.38 Million EUR | 102.54% |
| 2018 | 2.16 Million EUR | -2.35% |
| 2017 | 2.21 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.87 Million EUR | 0.0% |
| 2024 Q1 | 2.87 Million EUR | 40.28% |
| 2023 Q3 | 2.94 Million EUR | -11.53% |
| 2023 FY | 2.04 Million EUR | -31.91% |
| 2023 Q4 | 2.04 Million EUR | -30.48% |
| 2023 Q2 | 3.33 Million EUR | -0.03% |
| 2023 Q1 | 3.33 Million EUR | 10.74% |
| 2022 Q4 | 3 Million EUR | 0.03% |
| 2022 Q3 | 3 Million EUR | 80.28% |
| 2022 Q2 | 1.66 Million EUR | -49.29% |
| 2022 Q1 | 3.28 Million EUR | -37.39% |
| 2022 FY | 3 Million EUR | -42.74% |
| 2021 FY | 5.25 Million EUR | -9.21% |
| 2021 Q2 | 5.03 Million EUR | -4.22% |
| 2021 Q3 | 6.75 Million EUR | 34.29% |
| 2021 Q4 | 5.25 Million EUR | -22.28% |
| 2021 Q1 | 5.25 Million EUR | -9.18% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 5.78 Million EUR | -3.71% |
| 2020 Q3 | 6 Million EUR | 0.0% |
| 2020 FY | 5.78 Million EUR | 32.07% |
| 2019 FY | 4.38 Million EUR | 102.54% |
| 2018 FY | 2.16 Million EUR | -2.35% |
| 2017 FY | 2.21 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -86.013% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 95.418% |
| Adocia SA | 4.54 Million EUR | 54.89% |
| Biophytis S.A. | 3.11 Million EUR | 34.169% |
| Advicenne S.A. | 15.89 Million EUR | 87.116% |
| genOway Société anonyme | 5.51 Million EUR | 62.894% |
| IntegraGen SA | 642.28 Thousand EUR | -218.864% |
| Medesis Pharma S.A. | 1.2 Million EUR | -70.667% |
| Neovacs S.A. | 650 Thousand EUR | -215.077% |
| NFL Biosciences SA | 39.2 Thousand EUR | -5124.09% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 52.99% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -4.472% |
| Sensorion SA | 1.24 Million EUR | -65.04% |
| Theranexus Société Anonyme | 2.46 Million EUR | 16.772% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | 47.46% |
| TheraVet SA | 1 Million EUR | -104.677% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | 70.345% |
| argenx SE | 15.35 Million EUR | 86.661% |
| BioSenic S.A. | 15.57 Million EUR | 86.849% |
| Celyad Oncology SA | 902 Thousand EUR | -127.051% |
| DBV Technologies S.A. | 4.52 Million USD | 54.75% |
| Galapagos NV | 4.94 Million EUR | 58.576% |
| Genfit S.A. | 62.25 Million EUR | 96.71% |
| GeNeuro SA | 6.49 Million EUR | 68.455% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -495.349% |
| Innate Pharma S.A. | 30.6 Million EUR | 93.309% |
| Inventiva S.A. | 25.61 Million EUR | 92.005% |
| MaaT Pharma SA | 5.42 Million EUR | 62.249% |
| MedinCell S.A. | 52.8 Million EUR | 96.121% |
| Nanobiotix S.A. | 41.66 Million EUR | 95.084% |
| Onward Medical N.V. | 16.3 Million EUR | 87.44% |
| Oryzon Genomics S.A. | 3.45 Million EUR | 40.648% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | 94.232% |
| Oxurion NV | 117 Thousand EUR | -1650.427% |
| Pharming Group N.V. | 123.65 Million EUR | 98.344% |
| Poxel S.A. | 40.14 Million EUR | 94.898% |
| GenSight Biologics S.A. | 1.04 Million EUR | -95.42% |
| Transgene SA | 17 Thousand EUR | -11947.059% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 99.929% |
| Valneva SE | 132.76 Million EUR | 98.457% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |